A review of current treatment strategies for infective endocarditis

  title={A review of current treatment strategies for infective endocarditis},
  author={David Luque Paz and Ines Lakbar and Pierre Tattevin},
  journal={Expert Review of Anti-infective Therapy},
  pages={297 - 307}
ABSTRACT Introduction Infective endocarditis is one of the most difficult-to-treat infectious diseases. Areas covered We restricted this review to the anti-infective treatment of the main bacteria responsible for infective endocarditis, i.e. staphylococci, streptococci, enterococci, and Gram-negative bacilli, including HACEK. Specific topics of major interest in treatment strategy are covered as well, including empirical treatment, oral switch, and treatment duration. We searched in the MEDLINE… Expand
Current Challenges in the Management of Infective Endocarditis
This review aims to address the changing epidemiology of endocarditis, several recent advances in the understanding of the pathophysiology of Endocarditis-triggered sepsis, new useful diagnostic tools as well as current concepts in the medical and surgical management of this disease. Expand
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
A critical reappraisal of real-world use of dalbavancin for off-label indications is provided and it is shown that the promising efficacy in challenging scenarios, coupled with the unique pharmacokinetic/pharmacodynamic properties, makes dal BVancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections. Expand
The Dynamics of Infectious Diseases Associated With Injection Drug Use in Lawrence and Lowell, Massachusetts
Collecting data on other complications associated with injection drug use by public health departments may be important to consider because these complications may serve as input to a sentinel system to trigger early intervention and avert potential outbreaks of HIV. Expand


Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review
The use of oral ciprofloxacin in combination with rifampin for uncomplicated right-sided S. aureus IE in IVDUs is supported by one small clinical trial of relatively good quality and could be considered when conventional IV antibiotic therapy is not possible. Expand
Aminoglycosides for infective endocarditis: time to say goodbye?
In a scenario of progressive increase in the age and frailty of IE patients, the use of aminoglycosides can be reduced or avoided in ∼90% cases, which should result in reduced incidence of renal failure, an important prognostic factor in IE. Expand
Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients.
A cohort study of 426 cases of infective endocarditis over a period of 13 years, including 369 cases of definite IE according to the Duke criteria, finds that switching to oral administration was not associated with an increased risk of relapse or reinfection. Expand
Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis
In patients with endocarditis on the left side of the heart who were in stable condition, changing to oral antibiotic treatment was noninferior to continued intravenous antibiotic treatment. Expand
Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis.
In staphylococcal NVE, combination treatment is not superior to monotherapy in sterilizing infected valves, but in PVE combination treatment confers an advantage. Expand
Analysis of the 2015 American and European guidelines for the management of infective endocarditis.
The main changes brought upon by these guidelines, their discrepancies, and the 'pros' and 'cons' that may help you select the best treatment regimen for your patients are detailed. Expand
Addition of Rifampin to Standard Therapy for Treatment of Native Valve Infective Endocarditis Caused by Staphylococcus aureus
The results suggest that the potential for hepatotoxicity, drug-drug interactions, and the emergence of resistant S. aureus isolates warrants a careful risk-benefit assessment before adding rifampin to standard antibiotic treatment of native valve S.Aureus IE until further clinical studies are performed. Expand
Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis.
Twenty-three patients with prosthetic valve endocarditis caused by methicillin-resistant Staphylococcus epidermidis were studied retrospectively for assessment of the role of rifampin treatment and the rates of cure obtained were similar to those obtained with beta-lactam agents alone. Expand
Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations.
The path that led to current concepts regarding antimicrobial treatment of endocarditis caused by viridans streptococci highly susceptible to penicillin is presented and there are no predictors of cure that can be used to individualize treatment duration in patients with bacterialendocarditis. Expand
Update on blood culture-negative endocarditis.
The rate of non-documented infective endocarditis has decreased with the advent of molecular biology - improved performance for the diagnosis of bacterialendocarditis with blood cultures sterilized by previous antibacterial treatment - and cardiac surgery - access to the main infected focus, the endocardium, for half of the patients. Expand